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K e y  M e s s a g e s 
1. Compared with the Hong Kong general 
population norm, Chinese patients with 
colorectal neoplasm (CRN) reported worse 
physical health-related quality of life (HRQOL) 
but better mental HRQOL and comparable 
health preference scores. 
2. The CRN stage at diagnosis was the most 
significant determinant of HRQOL. Colorectal 
cancer was associated with worse physical 
HRQOL and health preference scores. 
3. Immunochemical faecal occult blood testing 
every 2 years is the most cost-effective colorectal 
cancer screening strategy, with an incremental 
cost-effectiveness ratio of HK$43 660 per quality-
Health-related quality of life in patients with 
colorectal neoplasm and cost-effectiveness of 
colorectal cancer screening in Hong Kong
Introduction
The prevalence of colorectal neoplasms (CRN), 
including both cancer and pre-cancerous polyps, 
has been estimated to be 21% in Hong Kong Chinese 
aged >50 years.1 Screening to detect early-stage CRN 
can reduce the incidence and mortality of colorectal 
cancers (CRC), but the cost-effectiveness of CRC 
screening in terms of quality-adjusted life years 
(QALYs) has never been evaluated in a Chinese 
population. This study aimed to determine the 
health-related quality of life (HRQOL) and health 
preference (utility) of patients with different stages 
of CRN and to evaluate the cost-effectiveness of CRC 
screening from the health care provider perspective 
in Hong Kong.
Methods
Between October 2009 and July 2010, 566 Chinese 
adult patients who were diagnosed with different 
stages of CRN for >6 months were recruited from the 
Queen Mary Hospital. The six stages of CRN were: 
(1) low-risk polyps (≤2 adenomas or 3-4 adenomas, 
all <1 cm), (2) high-risk polyps (≥5 adenomas or 
≥3 adenomas, at least one >1 cm), (3) stage I CRC, 
(4) stage II CRC, (5) stage III CRC, and (6) stage IV 
CRC. Patients were excluded if they had <6 months 
of life expectancy, were unable to communicate in 
Cantonese or too ill to carry out an interview, or had 
known cognitive impairment. 
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 A total of 553 (97.7%) patients completed 
an assessment by trained interviewers through 
telephone or face-to-face interview using a 
questionnaire that consisted of version 4 of the 
traditional Chinese (Hong Kong) Functional 
Assessment of Cancer Therapy-Colorectal Cancer 
(FACT-C), version 2 of the Chinese (Hong Kong) 
SF-12 Health Survey (SF-12v2), the Chinese version 
of the SF-6D Health Survey, and questions on socio-
demographic and clinical characteristics. 
 The HRQOL scores of the six CRN stages were 
compared using the one-way ANOVA with Tukey’s 
post hoc test. The HRQOL scores between CRN 
patients and the general population,2 and among 
different CRN groups were compared. The FACT-C 
total, health preference, and physical and mental 
component scores (PCS and MCS) of SF-12v2 
were used as dependent variables in the regression 
analysis. Multivariate linear regression analysis 
was used to determine the effect of clinical factors 
on dependent variables, controlling for the effects 
of socio-demographic factors. The R2 and adjusted 
R2 representing the total variances of dependent 
variables explained were reported together with 
the corresponding regression analyses. A P value of 
<0.05 was considered statistically significant.
 Using the Markov Model, a hypothetical static 
cohort of 100 000 Hong Kong people aged 50 years 
and their health histories were simulated by gender 
groups until 75 years old. The natural history of 
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adjusted life year gained. 
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CRN was reflected in the model via the transitions 
between different health states and mortalities. The 
health states of CRN were divided into four sections: 
(1) the pre-CRC section (normal colonic epithelium, 
low-risk polyps, and high-risk polyps), (2) the 
undiagnosed CRC section (undiagnosed stage I, stage 
II, stage III, and stage IV CRC), (3) the diagnosed 
CRC section (diagnosed stage I, stage II, stage III, 
and stage IV CRC), and (4) the death section (death 
from CRC, death from screening complications, 
and death from other causes). All health states were 
modelled as Markov states with a 1-year cycle. All 
health states were at risk of progression to a more 
advanced stage or death, but were prohibited from 
returning to former health states, except for patients 
with low-risk or high-risk polyps who could return to 
normal colonic epithelium following polypectomy. 
Undiagnosed CRC was at risk of progression to a 
more advanced stage of CRN and mortality from 
CRC or other causes. Each year, patients with 
undiagnosed CRN had a specific probability of being 
diagnosed that may be altered by screening. It was 
assumed that the risk of disease progression was 
eliminated once CRC was diagnosed and treated, 
but the risk of mortality from CRC or other causes 
remained. 
 Thirteen screening strategies were compared 
using a decision analytic model based on a state-
transition Markov process. The strategies were: (1) 
no screening (control), (2) annual guaiac faecal occult 
blood test (G-FOBT) [G-FOBT1], (3) annual human 
haemoglobin immunochemical-based FOBT (I-
FOBT) [I-FOBT1], (4) biennial G-FOBT (G-FOBT2), 
(5) biennial I-FOBT (I-FOBT2), (6) sigmoidoscopy 
every 5 years (SIG5), (7) sigmoidoscopy every 
10 years (SIG10), (8) colonoscopy every 5 years 
(COL5), (9) colonoscopy every 10 years (COL10), 
(10) annual G-FOBT plus sigmoidoscopy every 5 
years (G-FOBT1+SIG5), (11) annual G-FOBT plus 
sigmoidoscopy every 10 years (G-FOBT1+SIG10), 
* Higher scores indicate higher levels of functioning or quality of life 
†	 Significant	difference	between	the	six	colorectal	neoplasm	stages	by	Tukey	Post-hoc	multiple	comparisons
TABLE 1.  Baseline health-related quality of life and SF-6D preference scores by colorectal neoplasm stages
Scale* Hong 
Kong 
norm
Total 
(n=515)
Colorectal neoplasm stage Multiple 
comparison†
(1) Low 
risk (n=85)
(2) High 
risk (n=66)
(3) Stage I 
(n=80)
(4) Stage II 
(n=99)
(5) Stage 
III (n=109)
(6) Stage 
IV (n=76)
Mean±SD Functional 
Assessment of Cancer 
Therapy-Colorectal Cancer 
(FACT-C)
Physical well-being - 25.7±3.2 26.6±2.5 26.5±2.2 25.9±2.7 26.2±2.4 25.4±3.3 23.6±4.8 1,2,3,4,5>6
Social well-being - 19.9±4.3 20.3±3.7 19.3±4.5 20.0±4.0 20.3±4.6 19.9±4.5 19.6±4.1
Emotional well-being - 21.3±2.9 22.0±2.3 21.5±2.1 21.3±3.1 22.0±2.3 20.8±3.4 20.5±3.4 1,4>6; 1,4>5
Functional well-being - 18.9±4.4 19.9±4.0 19.2±3.2 19.1±5.1 19.7±3.7 18.7±4.2 16.5±4.8 1,2,3,4,5>6
Colorectal cancer subscale - 21.8±3.1 22.3±2.9 22.2±2.2 21.8±2.8 22.3±3.1 21.2±3.4 20.9±3.8 1,4>6
Trial outcome index - 66.4±8.8 68.8±7.2 67.9±5.9 66.8±8.5 68.2±7.6 65.2±9.1 61.0±11.2 1,2,3,4,5>6
FACT-G - 85.9±10.7 88.7±8.7 86.6±8.9 86.4±10.8 88.3±9.0 84.7±11.7 80.2±12.3 1,2,3,4>6
FACT-C - 107.6±12.7 111.0±10.2 108.8±9.9 108.2±12.8 110.6±11.0 105.8±13.8 101.1±15.0 1,2,3,4>6
Mean±SD SF-12 Health 
Survey
Physical functioning 86.7±23.0 78.5±29.6 85.0±24.8 84.1±25.8 77.2±30.3 85.1±25.2 75.7±30.7 63.5±34.5 1,2,3,4>6
Role physical 77.6±24.1 76.2±27.6 85.3±21.8 80.9±22.0 76.7±28.8 82.8±23.5 74.1±26.4 55.9±32.8 1>5; 1,2,3,4,5>6
Bodily pain 73.1±26.0 86.7±22.9 88.2±20.6 92.8±16.3 87.2±19.9 90.7±20.4 83.5±25.5 78.9±29.2 2,4>6
General health 45.6±27.6 52.3±25.8 55.4±24.6 49.9±22.6 53.6±27.1 57.9±24.6 52.0±26.0 43.0±27.7 1,4>6
Vitality 62.0±25.1 67.2±19.7 71.2±17.9 69.7±18.9 66.6±22.5 72.2±16.7 65.1±18.0 57.9±22.1 1,2,4>6
Social functioning 79.4±24.9 81.5±28.6 92.1±18.2 84.8±26.3 81.3±27.4 88.6±24.0 78.7±29.4 61.5±34.7 1>5; 1,2,3,4,5>6
Role emotional 73.5±21.8 89.3±19.4 91.9±16.2 91.7±14.8 91.6±17.8 91.4±18.7 88.4±19.4 80.3±25.7 1,2,3,4>6
Mental health 67.9±19.0 79.6±15.6 80.4±14.0 80.1±13.0 81.4±16.3 80.8±15.3 78.9±15.8 75.8±18.5
Physical component score 50.0±9.2 46.9±10.6 49.7±9.0 49.0±8.7 46.5±10.7 49.9±8.4 45.8±10.9 40.4±12.5 1,2,3,4,5>6
Mental component score 50.1±9.5 57.2±8.0 58.3±6.7 57.4±7.7 58.1±7.4 58.0±7.3 56.9±7.9 54.3±10.2 1,3,4>6
Mean±SD SF-6D Health 
Survey preference score
0.825±0.13 0.825±0.14 0.871±0.12 0.832±0.12 0.831±0.14 0.858±0.12 0.817±0.13 0.732±0.15 1,2,3,4,5>6
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(12) annual I-FOBT plus sigmoidoscopy every 5 
years (I-FOBT1+SIG5), and (13) annual I-FOBT plus 
sigmoidoscopy every 10 years (I-FOBT1+SIG10).
 The cost-effectiveness analysis was performed 
using the TreeAge Pro Suite 2009 Release 1.0.2 
(TreeAge Software, Williamstown [MA], US). 
Direct medical costs of CRN care from the health 
care provider perspective were used in the model. 
Data were extracted from a Hong Kong study3 
that estimated the local CRN costs for each stage 
of CRN. The incremental cost-effectiveness ratio 
(ICER) was calculated by dividing the incremental 
cost (∆C) by the incremental effectiveness (∆E) 
in terms of life-years (LY) and QALYs gained for 
a particular screening strategy compared with no 
screening.
*	 P<0.05
†	 HRQOL	scores	change	in	coefficient	for	each	unit	increase	in	independent	variable
TABLE 2.  Clinical and socio-demographic factors associated with health-related quality of life (HRQOL) scores in colorectal neoplasm (CRN) patients 
(n=515) by multivariate linear regression
Independent 
variables
FACT-C total score SF-12 physical component 
score
SF-12 mental component 
score
SF-6D
Coeff SE (95% CI) Coeff SE (95% CI) Coeff SE (95% CI) Coeff SE (95% CI)
Constant 89.21* 4.41 (80.57, 97.85) 39.81* 3.78 (32.41, 47.21) 45.40* 2.87 (39.78, 51.01) 0.6436* 0.0478 (0.5500, 0.7372)
Clinical factors
CRN stage 
(reference: stage IV)
Low-risk polyp 9.47* 1.99 (5.57, 13.37) 8.44* 1.66 (5.19, 11.69) 3.82* 1.26 (1.35, 6.28) 0.1248* 0.0210 (0.0837, 0.1659)
High-risk polyp 7.10* 2.08 (3.03, 11.17) 8.02* 1.73 (4.63, 11.42) 2.14 1.31 (-0.44, 4.71) 0.0841* 0.0219 (0.0411, 0.1270)
Stage I 5.79* 2.04 (1.78, 9.79) 5.49* 1.70 (2.15, 8.83) 3.74* 1.29 (1.21, 6.28) 0.0903* 0.0215 (0.0481, 0.1326)
Stage II 8.02* 1.90 (4.28, 11.75) 8.91* 1.59 (5.80, 12.02) 3.10* 1.20 (0.74, 5.46) 0.1143* 0.0201 (0.0749, 0.1537)
Stage III 4.18* 1.84 (0.56, 7.80) 4.89* 1.54 (1.88, 7.91) 2.61* 1.17 (0.33, 4.90) 0.0760* 0.0195 (0.0379, 0.1142)
Months since 
diagnosis†
0.02* 0.01 (0.00, 0.04) 0.02 0.01 (0.00, 0.03) 0.00 0.01 (-0.01, 0.01) 0.0002* 0.0001 (0.0000, 0.0005)
Primary (reference: 
sigmoid)
Colon -1.04 1.45 (-3.87, 1.79) -1.74 1.20 (-4.10, 0.62) 0.01 0.91 (-1.78, 1.80) -0.0073 0.0152 (-0.0372, 0.0225)
Rectum -1.25 1.43 (-4.05, 1.55) -2.81* 1.19 (-5.14, -0.47) -1.15 0.90 (-2.91, 0.62) -0.0302* 0.0150 (-0.0597, -0.0008)
Family history of 
colorectal cancer
-0.95 1.39 (-3.67, 1.77) 0.36 1.16 (-1.91, 2.62) -0.36 0.88 (-2.08, 1.36) 0.0047 0.0146 (-0.0240, 0.0333)
Chronic co-
morbidities (present)
-0.74 1.24 (-3.17, 1.68) -0.18 1.03 (-2.20, 1.84) -0.30 0.78 (-1.84, 1.23) -0.0090 0.0130 (-0.0346, 0.0165)
Socio-demographic 
factors
Male -0.24 1.26 (-2.71, 2.24) 0.42 1.05 (-1.64, 2.49) 2.06* 0.80 (0.49, 3.62) 0.0297* 0.0133 (0.0036, 0.0557)
Age† 0.22* 0.06 (0.10, 0.34) 0.04 0.05 (-0.06, 0.14) 0.16* 0.04 (0.08, 0.24) 0.0014* 0.0006 (0.0001, 0.0027)
Education (reference: 
tertiary)
No formal 
schooling
0.51 2.41 (-4.21, 5.24) -0.33 2.01 (-4.28, 3.61) 0.09 1.53 (-2.90, 3.08) 0.0026 0.0254 (-0.0472, 0.0525)
Primary -0.49 1.91 (-4.23, 3.26) 0.40 1.59 (-2.72, 3.52) -1.20 1.21 (-3.57, 1.17) 0.0056 0.0201 (-0.0339, 0.0450)
Secondary 0.44 1.76 (-3.01, 3.88) -0.43 1.47 (-3.31, 2.44) -0.23 1.11 (-2.40, 1.95) 0.0032 0.0185 (-0.0331, 0.0395)
Married 1.32 1.29 (-1.21, 3.84) 0.04 1.07 (-2.06, 2.15) -0.09 0.82 (-1.68, 1.51) 0.0046 0.0136 (-0.0221, 0.0312)
Currently working 1.72 1.54 (-1.31, 4.75) 1.55 1.29 (-0.97, 4.08) 0.77 0.98 (-1.15, 2.68) 0.0311 0.0163 (-0.0008, 0.0630)
Household monthly 
income ≤HK$20000
-3.06 1.71 (-6.42, 0.30) -1.89 1.43 (-4.69, 0.92) -0.65 1.08 (-2.78, 1.47) -0.0213 0.0181 (-0.0568, 0.0141)
Ever smoking 1.22 1.43 (-1.59, 4.03) 0.75 1.19 (-1.59, 3.09) -1.11 0.91 (-2.89, 0.66) 0.0209 0.0151 (-0.0087, 0.0505)
Ever drinking 0.28 1.41 (-2.49, 3.05) 0.26 1.18 (-2.05, 2.57) 0.23 0.89 (-1.52, 1.98) -0.0095 0.0149 (-0.0386, 0.0197)
R2 11.6%   11.9%   10.2%   14.8%   
Adjusted R2 8.0%   8.3%   6.6%   11.3%  
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Results
HRQOL of patients with colorectal 
neoplasms
Of the 553 subjects who completed the HRQOL 
evaluation at baseline, 479 (86.5%) and 414 (74.7%) 
completed the survey at 6 months and 12 months, 
respectively. The subjects’ SF-6D preference scores 
were comparable with the Hong Kong general 
population norm, except for those with stage III and 
IV CRC (Table 1). There was a progressive decline 
in HRQOL and health preference scores from low-
risk polyp to stage IV CRC. The FACT-C, SF-12v2 
subscores of physical functioning, role physical, 
general health, vitality, social functioning, PCS, and 
SF-6D health preference scores were higher (but not 
significantly) in patients with stage II CRC than with 
stage I CRC and high-risk polyp. 
Factors associated with HRQOL
Clinical and socio-demographic factors accounted for 
11.6%, 11.9%, 10.2%, and 14.8% of the total variations, 
as indicated by R2, in FACT-C total, PCS, MCS, 
and health preference scores of patients with CRN, 
respectively (Table 2). The health preference score was 
poorer in patients with rectal neoplasms but better 
in those diagnosed for a longer duration. The MCS 
and health preference scores were greater in males 
and older patients. Rectal neoplasms were associated 
with worse PCS compared to sigmoid neoplasms. The 
HRQOL score was not associated with chronic co-
morbidities or a family history of colorectal cancer, or 
socio-demographic factors such as educational level, 
marital status, working status, household income, 
smoking status, and drinking status.
Cost-effectiveness of CRC screening 
strategies
The ICER in terms of LY and QALYs gain of each 
screening strategy was compared with that of no 
screening (Table 3). The most effective strategy in 
terms of LY gained and QALY gained was I-FOBT1 
and I-FOBT1+SIG5, respectively. Compared with 
no screening, the most cost-effective strategy was 
I-FOBT2 at an ICER of HK$2 162 000 per LY gained, 
and HK$43 660 per QALY gained. Strategy I-FOBT1 
was more effective than I-FOBT2 at a slightly higher 
ICER of HK$51 610 per QALY gained.
Discussion
Patients with CRC reported worse PCS but better 
MCS. The health preference of Chinese patients 
with CRN was comparable with that of the general 
population norm in Hong Kong, except for those 
with advanced (stage III and IV) cancers. Patients 
with rectal CRN tended to report poorer HRQOL, as 
*	 G-FOBT1	denotes	annual	guaiac	faecal	occult	blood	test	(G-FOBT),	I-FOBT1	annual	human	haemoglobin	immunochemical-based	FOBT	(I-FOBT),	G-
FOBT2	biennial	G-FOBT,	I-FOBT2	biennial	I-FOBT,	SIG5	sigmoidoscopy	every	5	years,	SIG10	sigmoidoscopy	every	10	years,	COL5	colonoscopy	every	5	
years,	COL10	colonoscopy	every	10	years,	G-FOBT1+SIG5	annual	G-FOBT	plus	sigmoidoscopy	every	5	years,	G-FOBT1+SIG10	annual	G-FOBT	plus	
sigmoidoscopy	every	10	years,	I-FOBT1+SIG5	annual	I-FOBT	plus	sigmoidoscopy	every	5	years,	and	I-FOBT1+SIG10	annual	I-FOBT	plus	sigmoidoscopy	
every	10	years
TABLE 3.  Cost-effectiveness for each colorectal cancer screening strategy
Screening strategy* Cost per person 
(HK$)
Effectiveness Incremental cost-effectiveness ratio 
compared to control
Life years Quality-adjusted life 
years
$1000/life years $1000/quality-
adjusted life years
No screening (control) 1507.50 15.93831 15.62478 - -
G-FOBT1 21281.34 15.93953 15.75536 16256.42 151.43
I-FOBT1 13107.12 15.94238 15.84951 2851.50 51.61
G-FOBT2 11978.12 15.93924 15.70582 11241.73 129.20
I-FOBT2 9306.47 15.94192 15.80341 2162.08 43.66
SIG5 19369.06 15.94077 15.74849 7255.27 144.38
SIG10 11229.64 15.93957 15.69496 7697.89 138.52
COL5 24141.55 15.94217 15.79698 5869.72 131.44
COL10 14084.96 15.94065 15.73348 5380.46 115.70
G-FOBT1+SIG5 34923.60 15.94025 15.80462 17236.45 185.81
G-FOBT1+SIG10 29197.56 15.93981 15.77971 18393.31 178.72
I-FOBT1+SIG5 26169.89 15.94217 15.85910 6391.00 105.25
I-FOBT1+SIG10 20086.00 15.94221 15.85368 4760.06 81.16
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measured by the PCS and SF-6D preference scores. 
More attention should be paid to the rehabilitation 
of physical health for CRC survivors. The CRN stage 
at diagnosis was the most significant determinant 
of HRQOL and health preference, and indicates the 
importance of early detection of CRC. The SF-6D 
health preference scores by CRN stage would be 
useful for estimation of QALYs for cost-effectiveness 
analysis of interventions in CRN. 
 For the Chinese population in Hong Kong, 
strategy I-FOBT2 is the most cost-effective at 
an ICER of HK$43 660 per QALY gained, well 
below international thresholds of US$50 0004 and 
GBP$20 000.5 CRC screening strategies that utilised 
sigmoidoscopy, colonoscopy, or G-FOBT alone were 
dominated by strategies that include the I-FOBT 
for population-based screening of CRC in Chinese 
people. G-FOBT should no longer be the method 
of choice for CRC screening. Clinicians and health 
policy makers can take reference of these findings 
to develop evidence-based guidelines for CRC 
screening in the Chinese population of Hong Kong.
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